- Home
- CREV vs IBO Comparison
CREV vs IBO Comparison
Compare CREV & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- IBO
- Stock Information
- Founded
- CREV 2007
- IBO 2018
- Country
- CREV Ireland
- IBO United States
- Employees
- CREV N/A
- IBO N/A
- Industry
- CREV
- IBO
- Sector
- CREV
- IBO
- Exchange
- CREV Nasdaq
- IBO NYSE
- Market Cap
- CREV 5.7M
- IBO 5.8M
- IPO Year
- CREV N/A
- IBO 2024
- Fundamental
- Price
- CREV $2.86
- IBO $0.76
- Analyst Decision
- CREV
- IBO
- Analyst Count
- CREV 0
- IBO 0
- Target Price
- CREV N/A
- IBO N/A
- AVG Volume (30 Days)
- CREV 467.8K
- IBO 23.2M
- Earning Date
- CREV 05-14-2025
- IBO 08-23-2025
- Dividend Yield
- CREV N/A
- IBO N/A
- EPS Growth
- CREV N/A
- IBO N/A
- EPS
- CREV N/A
- IBO N/A
- Revenue
- CREV $39,261,077.00
- IBO N/A
- Revenue This Year
- CREV $40.76
- IBO N/A
- Revenue Next Year
- CREV $86.18
- IBO N/A
- P/E Ratio
- CREV N/A
- IBO N/A
- Revenue Growth
- CREV 41.52
- IBO N/A
- 52 Week Low
- CREV $2.00
- IBO $0.36
- 52 Week High
- CREV $14.19
- IBO $6.17
- Technical
- Relative Strength Index (RSI)
- CREV 50.99
- IBO N/A
- Support Level
- CREV $2.50
- IBO N/A
- Resistance Level
- CREV $4.09
- IBO N/A
- Average True Range (ATR)
- CREV 0.41
- IBO 0.00
- MACD
- CREV 0.05
- IBO 0.00
- Stochastic Oscillator
- CREV 37.63
- IBO 0.00
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.